Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus low-dose immunotherapy and chemotherapy in metastatic renal cell cancer
2005-005670-71Phase 2Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Nov 2006
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, aldesleukin, interferon alfa-2a, gemcitabine and fluorouracil in renal cell carcinoma (RCC), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Overall objective tumor response rate. Started Nov 2006; status: completed.
02
Drugs
bevacizumabaldesleukininterferon alfa-2agemcitabinefluorouracil
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2005-005670-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005670-71.